Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
0.8
USD
|
-23.08%
|
|
-1.36%
|
-1.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
310.7
|
322.4
|
69.8
|
44.32
|
80.15
|
102.9
|
-
|
-
|
Enterprise Value (EV)
1 |
310.7
|
322.4
|
8.894
|
-65.66
|
80.15
|
102.9
|
102.9
|
102.9
|
P/E ratio
|
-5.07
x
|
-6.56
x
|
-1.01
x
|
-0.82
x
|
-0.94
x
|
-3.35
x
|
-1.65
x
|
-1.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
26
x
|
16.5
x
|
3.78
x
|
3.11
x
|
3.98
x
|
1.86
x
|
8.7
x
|
17.6
x
|
EV / Revenue
|
26
x
|
16.5
x
|
3.78
x
|
3.11
x
|
3.98
x
|
1.86
x
|
8.7
x
|
17.6
x
|
EV / EBITDA
|
-6,259,736
x
|
-6,561,357
x
|
-906,147
x
|
-637,217
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7,106,010
x
|
-7,729,376
x
|
-888,127
x
|
-1,326,402
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.85
x
|
-
|
0.71
x
|
0.52
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,408
|
29,071
|
29,959
|
54,717
|
98,950
|
98,950
|
-
|
-
|
Reference price
2 |
12.23
|
11.09
|
2.330
|
0.8100
|
0.8100
|
1.040
|
1.040
|
1.040
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/24/22
|
3/15/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11.94
|
19.58
|
18.45
|
14.25
|
20.13
|
55.47
|
11.82
|
5.833
|
EBITDA
|
-49.64
|
-49.14
|
-77.03
|
-69.55
|
-
|
-
|
-
|
-
|
EBIT
1 |
-51.08
|
-53.28
|
-81.67
|
-73.16
|
-97.69
|
-28.92
|
-108.1
|
-137.6
|
Operating Margin
|
-427.78%
|
-272.08%
|
-442.73%
|
-513.4%
|
-485.34%
|
-52.14%
|
-914.26%
|
-2,358.58%
|
Earnings before Tax (EBT)
1 |
-
|
-44.08
|
-75.66
|
-64.68
|
-81.21
|
-79.41
|
-109.3
|
-114.9
|
Net income
1 |
-43.04
|
-44.08
|
-75.66
|
-64.92
|
-81.58
|
-46.1
|
-101.8
|
-132.3
|
Net margin
|
-360.38%
|
-225.09%
|
-410.15%
|
-455.58%
|
-405.29%
|
-83.11%
|
-860.62%
|
-2,268.46%
|
EPS
2 |
-2.410
|
-1.690
|
-2.300
|
-0.9900
|
-0.8600
|
-0.3100
|
-0.6300
|
-0.7050
|
Free Cash Flow
|
-43.73
|
-41.71
|
-78.6
|
-33.41
|
-
|
-
|
-
|
-
|
FCF margin
|
-366.19%
|
-212.98%
|
-426.05%
|
-234.5%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/24/22
|
3/15/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.895
|
1.445
|
2.746
|
2.23
|
7.828
|
3.176
|
2.679
|
6.867
|
7.407
|
36.6
|
7
|
5.633
|
6.233
|
2
|
2
|
EBITDA
|
-20.82
|
-
|
-
|
-
|
-12.68
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.05
|
-20.15
|
-18.43
|
-20.99
|
-13.59
|
-22.66
|
-21.47
|
-22.67
|
-30.9
|
11.11
|
-9.708
|
-15.32
|
-16.27
|
-
|
-
|
Operating Margin
|
-566.03%
|
-1,394.26%
|
-671.05%
|
-941.39%
|
-173.58%
|
-713.38%
|
-801.49%
|
-330.13%
|
-417.11%
|
30.35%
|
-138.69%
|
-271.95%
|
-260.98%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.24
|
-17.97
|
-16.36
|
-18.28
|
-12.08
|
-19.68
|
-18.02
|
-19.07
|
-24.65
|
14.38
|
-8.453
|
-23.74
|
-24.06
|
-
|
-
|
Net income
1 |
-21.24
|
-17.97
|
-16.36
|
-18.28
|
-12.31
|
-19.68
|
-18.02
|
-19.07
|
-24.82
|
14.38
|
-18.6
|
-17.9
|
-20.3
|
-
|
-
|
Net margin
|
-545.19%
|
-1,243.46%
|
-595.63%
|
-819.73%
|
-157.27%
|
-619.65%
|
-672.49%
|
-277.65%
|
-335.06%
|
39.3%
|
-265.71%
|
-317.75%
|
-325.67%
|
-
|
-
|
EPS
2 |
-0.6400
|
-0.4000
|
-0.2300
|
-0.2500
|
-0.1600
|
-0.2700
|
-0.2200
|
-0.1700
|
-0.2200
|
0.1100
|
-0.1450
|
-0.1300
|
-0.1400
|
-0.1700
|
-0.1800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/16/22
|
8/11/22
|
11/14/22
|
3/15/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
60.9
|
110
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-43.7
|
-41.7
|
-78.6
|
-33.4
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-36.5%
|
-32.2%
|
-61.6%
|
-67.6%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-29.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
143.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.600
|
-
|
3.270
|
1.560
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.340
|
-1.510
|
-2.010
|
-0.3100
|
-
|
-
|
-
|
-
|
Capex
|
2
|
2.37
|
12.6
|
5.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
16.74%
|
12.11%
|
68.2%
|
35.21%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/24/22
|
3/15/23
|
3/22/24
|
-
|
-
|
-
|
Last Close Price
1.04
USD Average target price
4.6
USD Spread / Average Target +342.31% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.23% | 103M | | +38.51% | 728B | | +33.05% | 603B | | -6.23% | 360B | | +18.78% | 332B | | +1.35% | 279B | | +16.00% | 244B | | +8.09% | 207B | | -5.77% | 205B | | +6.19% | 164B |
Other Pharmaceuticals
|